- Home
- AGIO vs CSAN Comparison
AGIO vs CSAN Comparison
Compare AGIO & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- CSAN
- Stock Information
- Founded
- AGIO 2007
- CSAN 1936
- Country
- AGIO United States
- CSAN Brazil
- Employees
- AGIO N/A
- CSAN N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- CSAN Retail-Auto Dealers and Gas Stations
- Sector
- AGIO Health Care
- CSAN Consumer Discretionary
- Exchange
- AGIO Nasdaq
- CSAN Nasdaq
- Market Cap
- AGIO 2.4B
- CSAN 2.1B
- IPO Year
- AGIO 2013
- CSAN N/A
- Fundamental
- Price
- AGIO $40.16
- CSAN $4.68
- Analyst Decision
- AGIO Strong Buy
- CSAN Hold
- Analyst Count
- AGIO 4
- CSAN 3
- Target Price
- AGIO $59.33
- CSAN $9.47
- AVG Volume (30 Days)
- AGIO 567.8K
- CSAN 2.2M
- Earning Date
- AGIO 10-30-2025
- CSAN 11-14-2025
- Dividend Yield
- AGIO N/A
- CSAN N/A
- EPS Growth
- AGIO N/A
- CSAN N/A
- EPS
- AGIO N/A
- CSAN N/A
- Revenue
- AGIO $44,791,000.00
- CSAN $7,993,490,490.00
- Revenue This Year
- AGIO $25.57
- CSAN $271.64
- Revenue Next Year
- AGIO $153.24
- CSAN $1.43
- P/E Ratio
- AGIO N/A
- CSAN N/A
- Revenue Growth
- AGIO 36.26
- CSAN 7.98
- 52 Week Low
- AGIO $23.42
- CSAN $3.80
- 52 Week High
- AGIO $62.58
- CSAN $8.64
- Technical
- Relative Strength Index (RSI)
- AGIO 45.66
- CSAN 52.89
- Support Level
- AGIO $38.90
- CSAN $4.29
- Resistance Level
- AGIO $44.10
- CSAN $4.73
- Average True Range (ATR)
- AGIO 1.72
- CSAN 0.19
- MACD
- AGIO -0.44
- CSAN 0.03
- Stochastic Oscillator
- AGIO 24.58
- CSAN 46.38
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.